US20080026031A1 - Implantable polymeric device for sustained release of buprenorphine - Google Patents

Implantable polymeric device for sustained release of buprenorphine Download PDF

Info

Publication number
US20080026031A1
US20080026031A1 US11801302 US80130207A US2008026031A1 US 20080026031 A1 US20080026031 A1 US 20080026031A1 US 11801302 US11801302 US 11801302 US 80130207 A US80130207 A US 80130207A US 2008026031 A1 US2008026031 A1 US 2008026031A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
buprenorphine
implantable
devices
device
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11801302
Inventor
Rajesh Patel
Louis Bucalo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Titan Pharmaceuticals Inc
Original Assignee
Titan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/048Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/12Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L31/125Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances

Abstract

The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • [0001]
    This application claims the benefit of U.S. Provisional Patent Application Ser. No. 60/384,733, filed May 31, 2002, the disclosure of which is incorporated herein by reference in its entirety.
  • STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
  • [0002]
    This invention was made in part during work supported by a grant from the National Institute of Mental Health (1R43 MH60037-01). The government has certain rights in the invention.
  • TECHNICAL FIELD
  • [0003]
    The invention provides a nonbioerodible, polymeric device for subcutaneous implantation and sustained release of buprenorphine for treatment of opiate addiction or pain.
  • BACKGROUND OF THE INVENTION
  • [0004]
    Buprenorphine, a semi-synthetic opiate classified as a “partial agonist” behaves very much like classical mu agonists such as morphine, exerting an analgesic effect through high affinity binding to mu subclass opiate receptors in the central nervous system.
  • [0005]
    Buprenorphine has been used as an analgesic for treatment of moderate to severe pain in postoperative cancer patients. Therapeutic doses administered by intravenous and intramuscular routes range from 0.3 to 0.6 mg. Buprenorphine produces effects similar to morphine but is 25-40 times more potent and has a large therapeutic index. Buprenorphine stimulates the mu opiate receptors in the brain and produces effects associated with other mu agonists such as morphine. Such effects include analgesia, euphoria, sedation, and respiratory depression. For this reason, oral buprenorphine formulations have the potential for misuse (i.e., diversion for recreational, rather than therapeutic, purposes), making them unsuitable for use as a take-home medication.
  • [0006]
    Many patients with chronic pain require long-term continuous dosing with opiate analgesics. Effective treatment often necessitates the ingestion of multiple tablets per day. Compliance with this dosing scheme is often poor. Further, enteral drug delivery is poorly tolerated or prohibited in patients with particular indications, such as some patients with cancer-related pain in whom continuous drug delivery is a necessity. However, continuous parenteral delivery of opiate analgesics is expensive, cumbersome, and dependent upon the availability of refrigeration, catheters, pumps, and trained personnel. Further, concerns over drug diversion for illicit use often limits availability of opiate analgesics. An oral tablet containing a combination of buprenorphine and naloxone, an opiate receptor antagonist, has been developed to address this issue (see, e.g., U.S. Pat. No. 4,935,428). If an opiate addict attempts to abuse the combination tablet by dissolving it and injecting it intravenously, unpleasant withdrawal symptoms brought on by the naloxone component will result. However, opiate antagonists such as naloxone may reduce the analgesic effectiveness of buprenorphine to those who are using it therapeutically for pain relief and such antagonists may cause undesirable side effects. Thus, there is a need for an improved buprenorphine formulation which is administrable to those in need of analgesia but which provides a lower potential for abuse.
  • [0007]
    Buprenorphine has also been studied as a treatment for addiction to heroin and other opiates. Opiate addiction is a major societal problem throughout the world. The general treatment program for such addiction includes incorporation of a drug substitute, e.g., methadone, into an oral formulation for administration to the drug addict. Typically, such drug substitutes function by binding to receptors specific for the drug of abuse. The effectiveness of such treatment depends largely upon adherence to an established treatment schedule. Often, poor compliance with dosing regimens complicates treatment. Further, the cost of such therapy is significant, a large portion of the cost relating to frequent clinic visits and the monitoring of urine tests to assure compliance with drug dosing, as well as pharmacy charges relating to dispensing of methadone. Another problem with oral dosage forms such as powders or tablets is that they can be dissolved in water and concentrated to provide a solution which may be injected by the addict in lieu of the drug of abuse. A means for long-term continuous administration of a drug suitable for treatment of opiate dependency in a form that is not subject to potential abuse, would significantly reduce the compliance problems encountered in drug addiction treatment programs.
  • [0008]
    Buprenorphine's unique effects and pharmacology make it a clinically attractive treatment option for opiate dependency. For example, buprenorphine produces less euphoria than morphine and heroin. When compared with other opiates, it also causes a significantly lower degree of sedation. Further, direct dependence studies have shown little physical dependence upon withdrawal of the drug.
  • [0009]
    There is a need for a buprenorphine formulation, suitable for long-term, continuous administration, that will improve compliance for both pain relief and drug dependency treatment regimens. There is also a need for a buprenorphine formulation that will reduce abuse potential, and in which the addition of an antagonist such as naloxone will not be necessary.
  • BRIEF SUMMARY OF THE INVENTION
  • [0010]
    The invention provides compositions (i.e., implantable polymeric devices), methods, and kits for treatment of opiate addiction and pain.
  • [0011]
    In one aspect the invention provides an implantable device for treating opiate addiction, comprising buprenorphine and a biocompatible, nonerodible polymeric matrix, wherein said buprenorphine is encapsulated within said matrix, and wherein when said implantable device is implanted subcutaneously in a mammal, said buprenorphine is continuously released in vivo over a sustained period of time through pores that open to the surface of said matrix at a rate that results in a steady state plasma buprenorphine level of at least about 0.1 ng/ml, typically in the range of about 0.1 to about 70 ng/ml. In some embodiments, the steady state plasma buprenorphine level is about 1 to about 10 ng/ml. In other embodiments, the steady state plasma buprenorphine level is about 1 to about 6 ng/ml. In some embodiments, the polymeric matrix comprises ethylene vinyl acetate copolymer (EVA). In some embodiments wherein the implantable device comprises EVA, the vinyl acetate content is about 33% by weight. The implantable devices generally comprise about 10% to about 85%, often about 50% to about 75% buprenorphine. In one embodiment, the implantable device comprises about 50% buprenorphine. In another embodiment, the implantable device comprises about 75% buprenorphine. In various embodiments, the sustained period of time for buprenorphine release is from about 3 months to about 1 year, or longer, e.g., at least about 3, 6, 9, or 12 months. In some embodiments, the implantable device for treatment of opiate addiction is produced by an extrusion process. In one embodiment, extruded devices comprise dimensions of about 2.4 mm in diameter and about 2.6 cm in length. In other embodiments, extruded devices comprise dimensions of about 2 to about 3 mm in diameter and about 2 to about 3 cm in length. In further embodiments, extruded devices comprises dimensions of about 0.5 to about 7 mm in diameter and about 0.5 to about 1.0 cm in length. In some embodiments in which extruded devices comprise dimensions of about 2.4 mm in diameter and about 2.6 cm in length, the devices each release about 1 mg buprenorphine per day in vitro.
  • [0012]
    In another aspect, the invention provides an implantable device for treating pain, comprising buprenorphine and a biocompatible, nonerodible polymeric matrix, wherein said buprenorphine is encapsulated within said matrix, and wherein when said implantable device is subcutaneously implanted in a mammal, said buprenorphine is continuously released in vivo over a sustained period of time through pores that open to the surface of said matrix at a steady state rate of at least about 0.1 mg per day, generally in the range of about 0.1 to about 5 mg per day. In some embodiments, the steady state rate of buprenorphine release is about 0.3 mg per day. In some embodiments, the polymeric matrix comprises EVA. In some embodiments wherein the implantable device comprises EVA, the vinyl acetate content is about 33% by weight. The implantable devices generally comprise about 10% to about 85%, often about 50% to about 75% buprenorphine. In one embodiment, the implantable device comprises about 50% buprenorphine. In another embodiment, the implantable device comprises about 75% buprenorphine and about 25% EVA. In various embodiments, the sustained period of time for buprenorphine release is from about 3 months to about 1 year, or longer, e.g., at least about 3, 6, 9, or 12 months. In some embodiments, the implantable device for treatment of pain is produced by an extrusion process. In one embodiment, extruded devices comprise dimensions of about 2.4 mm in diameter and about 2.6 cm in length. In other embodiments, extruded devices comprise dimensions of about 2 to about 3 mm in diameter and about 2 to about 3 cm in length. In further embodiments, extruded devices comprises dimensions of about 0.5 to about 7 mm in diameter and about 0.5 to about 10 cm in length. In some embodiments in which extruded devices comprise dimensions of about 2.4 mm in diameter and about 2.6 cm in length, the devices each release about 1 mg buprenorphine per day in vitro.
  • [0013]
    In one aspect, the invention provides a method for treatment of opiate addiction, comprising administering at least one implantable device for treatment of opiate addiction, as described above, subcutaneously, wherein each of said at least one implantable devices comprises buprenorphine encapsulated within a biocompatible, nonerodible polymeric matrix, wherein said buprenorphine is continuously released in vivo over a sustained period of time through pores that open to the surface of said matrix at a rate that results in a steady state plasma buprenorphine level of at least about 0.1 ng/ml, generally about 0.1 to about 70 ng/ml. In some embodiments, the steady state plasma level of buprenorphine is about 1 to about 10 ng/ml. In other embodiments, the steady state plasma level of buprenorphine is about 1 to about 6 ng/ml. In one embodiment, the method includes a multiplicity of individual implantable devices, wherein the combination of the implantable devices continuously releases buprenorphine in vivo over a sustained period of time at a steady state rate that results in a plasma buprenorphine level of about 0.1 to about 70, about 1 to about 10, or about 1 to about 6 ng/ml. In some embodiments, the polymeric matrix comprises EVA. In one embodiment, implantable devices comprise about 75% buprenorphine and about 25% EVA. In another embodiment, implantable devices comprise about 50% buprenorphine. In some embodiments wherein implantable devices comprise EVA, the vinyl acetate content is about 33% by weight. In various embodiments, the sustained period of time for buprenorphine release is from about 3 months to about 1 year, or longer, e.g., at least about 3, 6, 9, or 12 months. In some embodiments, implantable devices for treatment of opiate addiction are produced by an extrusion process. In one embodiment, extruded devices comprise dimensions of about 2.4 mm in diameter and about 2.6 cm in length. In other embodiments, extruded devices comprises dimensions of about 2 to about 3 mm in diameter and about 2 to about 3 cm in length. In further embodiments, extruded devices comprise dimensions of about 0.5 to about 7 mm in diameter and about 0.5 to about 10 cm in length. In some embodiments in which extruded devices comprises dimensions of about 2.4 mm in diameter and about 2.6 cm in length, the devices each release about 1 mg buprenorphine per day in vitro. In methods of the invention, the implantable devices are administered by subcutaneous implantation. In various embodiments, the devices are subcutaneously implanted at a site selected from the group consisting of the upper arm, the back, and the abdomen.
  • [0014]
    In another aspect, the invention provides a method for treatment of pain, comprising administering at least one implantable device for treatment of pain, as described above, subcutaneously, wherein each of said at least one implantable devices comprises buprenorphine encapsulated within a biocompatible, nonerodible polymeric matrix, wherein said buprenorphine is continuously released in vivo over a sustained period of time through pores that open to the surface of said matrix at a steady state rate of at least about 0.1 mg per day, often in the range of about 0.1 to about 5 or about 0.2 to about 1 mg per day. In some embodiments, the steady state rate of buprenorphine release is about 0.3 mg per day. In one embodiment, the method includes a multiplicity of individual implantable devices, wherein the combination of the implantable devices continuously releases buprenorphine in vivo over a sustained period of time at a steady state rate of about 0.1 to about 5, about 0.2 to about 1; or about 0.3 mg per day. In some embodiments, the polymeric matrix comprises EVA. In one embodiment, implantable devices comprise about 75% buprenorphine and about 25% EVA. In another embodiment, implantable devices comprise about 50% buprenorphine. In some embodiments wherein implantable devices comprise EVA, the vinyl acetate content is about 33% by weight. In various embodiments, the sustained period of time for buprenorphine release is from about 3 months to about 1 year, or longer, e.g., at least about 3, 6, 9, or 12 months. In some embodiments, implantable devices for treatment of pain are produced by an extrusion process. In methods of the invention, the implantable devices are administered by subcutaneous implantation. In various embodiments, the devices are subcutaneously implanted at a site selected from the group consisting of the upper arm, the back, and the abdomen.
  • [0015]
    In one aspect, the invention provides a kit for use in treatment of opiate addiction, comprising at least one implantable device for treatment of opiate addiction, as described above, comprising buprenorphine encapsulated within a biocompatible, nonerodible polymeric matrix, wherein when said at least one implantable device is implanted subcutaneously in a mammal, said buprenorphine is continuously released in vivo over a sustained period of time through pores that open to the surface of said matrix at a rate that results in a steady state plasma level of about 0.1 to about 70 ng/ml, and instructions for use. In some embodiments, the steady state plasma level is about 1 to about 10 ng/ml. In other embodiments, the steady state plasma level is about 1 to about 6 ng/ml. In some embodiments, kits include a multiplicity of individual implantable devices, wherein when said multiplicity of devices is implanted subcutaneously in a mammal, the combination of the implantable devices continuously releases buprenorphine in vivo over a sustained period of time at a rate that results in a steady state plasma level of about 0.1 to about 70, often about 1 to about 10, more often about 1 to about 6 ng/ml. In one embodiment, each of the individual implantable devices releases buprenorphine at a rate of about 1 mg per day in vitro. In some embodiments, the polymeric matrix comprises EVA. In various embodiments, implantable devices comprise about 10 to about 85% buprenorphine. In some embodiments wherein implantable devices comprise EVA, the vinyl acetate content is about 33% by weight.
  • [0016]
    In another aspect, the invention provides a kit for use in treatment of pain, comprising at least one implantable device for treatment of pain, as described above, comprising buprenorphine encapsulated within a biocompatible, nonerodible polymeric matrix, wherein when said at least one implantable device is implanted subcutaneously in a mammal, said buprenorphine is continuously released in vivo over a sustained period of time through pores that open to the surface at a steady state rate of at least about 0.1 mg per day, generally in the range of about 0.1 to about 5 or about 0.2 to about 1 mg per day, and instructions for use. In one embodiment, the steady state rate of buprenorphine release is about 0.3 mg per day. In some embodiments, kits include a multiplicity of individual implantable devices, wherein when said multiplicity of devices is implanted subcutaneously in a mammal, the combination of the implantable devices continuously releases buprenorphine in vivo over a sustained period of time at a rate of about 0.1 to about 5, 0.2 to about 1, or about 0.3 mg per day. In some embodiments, the polymeric matrix comprises EVA. In various embodiments, implantable devices comprise about 10 to about 85% buprenorphine. In some embodiments wherein implantable devices comprise EVA, the vinyl acetate content is about 33% by weight.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0017]
    FIG. 1 depicts in vitro release of buprenorphine over time from a single irradiated extruded rod containing 75% buprenorphine HCl and 25% EVA (33% vinyl acetate). FIG. 1A shows the average cumulative release of buprenorphine HCl in 0.5% SDS at 37° C. FIG. 1B shows the average daily release of buprenorphine HCl in 0.5% SDS at 37° C.
  • [0018]
    FIG. 2 depicts in vivo release of buprenorphine from devices of the invention implanted subcutaneously in dogs for 84 days. Two devices, each with dimensions of about 2.6 cm in length and about 2 mm in diameter, and containing 75% buprenorphine HCl and 25% EVA (33% vinyl acetate); were implanted in each dog.
  • [0019]
    FIG. 3 depicts in vivo release of buprenorphine when 8, 16, or 24 implantable devices were implanted subcutaneously in dogs for 8 months.
  • [0020]
    FIG. 4 depicts the steady state plasma concentration of buprenorphine achieved when 2, 8, 16, or 24 implantable devices were implanted subcutaneously in dogs.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0021]
    The invention provides a biocompatible, nonerodible polymeric device, which permits controlled, sustained release of buprenorphine over extended periods of time when implanted subcutaneously in an individual in need of treatment.
  • [0022]
    Continuous release of a compound in vivo over an extended duration may be achieved via implantation of a device containing the compound encapsulated in a nonerodible polymeric matrix. Examples of implantable, nonerodible polymeric devices for continuous drug release are described in, e.g., U.S. Pat. Nos. 4,883,666, 5,114,719, and 5,601,835. Implantable devices improve compliance with drug dosing regimens, due to continuous release of the drug from the polymeric matrix, and reduce abuse potential since such devices are not as subject to diversion as other formulations, such as, for example, oral dosage forms.
  • [0023]
    Implantation of the device and extended release of buprenorphine limits or prevents diversion of the drug to nonintended users and improves compliance with dosing regimens, eliminating the need for repeated injections or ingestion of pills or tablets. An implantable, sustained-release device according to the present invention also permits achievement of more constant blood levels of buprenorphine than injectable or oral dosage forms, thereby minimizing side effects.
  • [0024]
    Previous vehicles for long term delivery of buprenorphine have included biodegradable polymers (U.S. Pat. No. 5,486,362). However, in contrast to the present invention, such polymers do not release compounds at linear rates for extended time periods of several months or longer, because channels form in the matrix as it erodes, resulting in increased release rates over time. The present invention includes a biocompatible, nonerodible polymer that exhibits generally linear release kinetics for buprenorphine in vivo, after an initial burst.
  • [0000]
    Implantable Polymeric Devices for Treatment of Opiate Addiction or Pain
  • [0025]
    The invention includes implantable devices for treatment of opiate addiction or pain, including buprenorphine encapsulated in a polymeric, nonerodible matrix. As used herein, “buprenorphine” refers to buprenorphine free base and pharmaceutically acceptable salts thereof, such as buprenorphine HCl, and norbuprenorphine. Incorporation of buprenorphine into the polymeric matrix causes the formation of a series of interconnecting channels and pores that are accessible to the surface for release of the drug. Where appropriate, a coating that is impermeable to the drug is placed over at least a portion of the device to further regulate the rate of release. When implanted subcutaneously, devices of the invention continuously release buprenorphine for an extended period of time with a pseudo or near zero order release rate. After an initial burst following implantation, release rates are typically within about 10-20% of the steady state average. In some embodiments, the initial burst of buprenorphine released in vivo after implantation is reduced or minimized by prewashing the implantable devices before implantation to remove surface buprenorphine. Prewashing may be performed in any solution in which buprenorphine is soluble, for example 30 minutes in ethanol or normal saline.
  • [0026]
    As used herein, “nonerodible matrix” refers to a polymeric carrier that is sufficiently resistant to chemical and/or physical destruction by the environment of use such that the matrix remains essentially intact throughout the release period. The polymer is generally hydrophobic so that it retains its integrity for a suitable period of time when placed in an aqueous environment, such as the body of a mammal, and stable enough to be stored for an extended period before use. The ideal polymer must also be strong, yet flexible enough so that it does not crumble or fragment during use. Nonerodible matrices remain intact in vivo for extended periods of time, typically months or years. Drug molecules encapsulated in the matrix are released over time via diffusion through channels and pores in a sustained and predictable manner. The release rate can be altered by modifying the percent drug loading, porosity of the matrix, structure of the implantable device, or hydrophobicity of the matrix, or by adding a hydrophobic coating to the exterior of the implantable device.
  • [0027]
    Typically, ethylene vinyl acetate copolymer (EVA) is used as the polymeric matrix, but other nonerodible materials may be used. Examples of other suitable materials include silicone, hydrogels such as crosslinked poly(vinyl alcohol) and poly(hydroxy ethylmethacrylate), acyl substituted cellulose acetates and alkyl derivatives thereof, partially and completely hydrolyzed alkylene-vinyl acetate copolymers, unplasticized polyvinyl chloride, crosslinked homo- and copolymers of polyvinyl acetate, crosslinked polyesters of acrylic acid and/or methacrylic acid, polyvinyl alkyl ethers, polyvinyl fluoride, polycarbonate, polyurethane, polyamide, polysulphones, styrene acrylonitrile copolymers, crosslinked poly(ethylene oxide), poly(alkylenes), poly(vinyl imidazole), poly(esters), poly(ethylene terephthalate), polyphosphazenes, and chlorosulphonated polyolefines, and combinations thereof.
  • [0028]
    Implantable devices of the invention are typically formulated with buprenorphine loading of about 10% to about 85%. Often, the devices include about 50% to about 75% buprenorphine. Devices are sometimes formulated as compositions including about 75% buprenorphine and about 25% EVA (33% vinyl acetate). In various embodiments, devices include any of at least about 10, 20, 30, 40, 50, 55, 60, 65, 70, 75, 80, or 85% buprenorphine. Devices may be produced using an extrusion process, wherein ground EVA is blended with buprenorphine, melted, and extruded into rod-shaped structures. Rods are cut into individual implantable devices of the desired length, packaged, and sterilized prior to use. Other methods for encapsulating therapeutic compounds in implantable polymeric, nonerodible matrices are well known to those of skill in the art. Such methods include, for example, solvent casting (see, e.g., U.S. Pat. Nos. 4,883,666, 5,114,719, and 5,601,835). A skilled artisan would be able to readily determine an appropriate method of preparing such an implantable device, depending on the shape, size, drug loading, and release kinetics desired for a particular type of patient or clinical indication.
  • [0029]
    Devices of the invention are suitable for sustained release of buprenorphine for treatment of opiate addiction or pain. As used herein, “sustained release” refers to the release of buprenorphine such that the blood concentration remains within the therapeutic range but below toxic levels for an extended duration. Devices of the invention generally exhibit near zero-order pharmacokinetics in vivo, similar to kinetics achieved with an IV drip, but without the need for external medical equipment and personnel associated with intravenous methods. Generally, after implantation, the devices release therapeutically effective amounts of buprenorphine for periods of several months up to one year or longer. Often, the duration of implantation, with continuous release of buprenorphine, is from about 3 months to about 2 years, about 3 months to about 1 year, about 3 months to about 9 months, or about 3 months to about 6 months. In various embodiments, therapeutically effective amounts of buprenorphine are released for at least about 3, 6, 9, 12, 15, 18, 21, or 24 months.
  • [0030]
    Multiple implantable devices may be used, or the size and shape of the devices may be modified, to achieve a desired overall dosage. Implantable devices are often about 0.5 to about 10, more often about 1.5 to about 5, most often about 2 to about 3 cm in length, and are often about 0.5 to about 7, more often about 1.5 to about 5, most often about 2 to about 3 mm in diameter. The release rate of implantable devices may also be modified by changing the vinyl acetate content in the EVA polymer matrix. The vinyl acetate content is often about 2 to about 40, more often about 10 to about 35, most often about 30 to about 35% by weight.
  • [0031]
    The desired dosage rate will depend upon factors such as the underlying condition for which buprenorphine is being administered, and the physiology of a particular patient, but will be readily ascertainable to physicians. For treatment of opiate addiction, buprenorphine is desirably released at a rate that maintains plasma levels of the drug at a therapeutically effective level. Often, a desirable plasma level of buprenorphine for treatment of opiate addiction is in the range of about 0.1 to about 70 ng/ml, more often about 1 to about 10 ng/ml, most often about 1 to about 6 ng/ml. In various embodiments for treatment of opiate addiction, buprenorphine is released from one or more devices in vivo at a rate that results in a plasma level of at least about 0.1, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 15, 25, 50, or 70 ng/ml. For treatment of pain, a therapeutically effective amount of buprenorphine is typically about 0.1 to about 5 mg/day, sometimes about 0.2 to about 1 mg/day, often about 0.3 mg/day, but may be modified depending upon the nature of the pain condition being treated and the particular patient involved. In various embodiments for treatment of pain, one or more devices are used that are capable of releasing at least about 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, or 5 mg/day in vivo or in vitro. As used herein, “therapeutically effective amount” or “therapeutically effective level” refers to the amount of buprenorphine that will render a desired therapeutic outcome (i.e., reduction of self-administration of nonprescribed drugs, or analgesic relief of pain).
  • METHODS OF THE INVENTION
  • [0032]
    The invention provides methods for treatment of opiate addiction and pain. Methods of the invention include subcutaneous administration of one or more polymeric implantable devices which include buprenorphine encapsulated within a biocompatible, nonerodible polymeric matrix such as EVA, and release of buprenorphine in a controlled manner over an extended period of time through multiple pores that open to the surface of the implantable device(s). Often, implantable devices are produced via an extrusion process, as described above.
  • [0033]
    Implantable devices are administered by subcutaneous implantation to an individual in need of treatment. As used herein, “individual” refers to a mammal, typically a human in need of treatment for opiate addiction or pain. Generally, implantable devices are administered by subcutaneous implantation at sites on the upper arm, back, or abdomen of an individual. Other suitable sites for administration may be readily determined by a medical professional. Multiple implantable devices may be administered to achieve a desired dosage for treatment.
  • [0034]
    Typically, in a method for treatment of opiate addiction, an implantable device or devices are administered that will release buprenorphine at a rate that will maintain a therapeutically effective plasma level for an extended period of time of at least about 3 months. When multiple devices are administered, the combination of the devices releases buprenorphine at a rate that will achieve a therapeutically effective plasma level. A therapeutically effective plasma level for treatment of opiate addiction is often about 0.1 to about 70 ng/ml, more often about 1 to about 10 ng/ml, most often about 1 to about 6 ng/ml. Often, sustained release at this dosage rate occurs for about 3 months to about 1 year or longer (e.g., at least about 3, 6, 9, or 12 months). As used herein, “opiate addiction” or “opiate dependency” refers to dependence by an individual on an opiate substance which is treatable by administration of a substitute substance, such as methadone or buprenorphine. It is anticipated that the implantable devices of the invention will alleviate compliance and diversion problems encountered with traditional methadone treatment regimens, as described above.
  • [0035]
    Further, in accordance with the present invention, a method of alleviating pain is provided which includes subcutaneous administration of an implantable nonerodible polymeric device which releases an analgesically effective amount of buprenorphine in a controlled manner for an extended period of time, i.e. about 3 months to about 1 year (e.g., at least about 3, 6, 9, or 12 months) or longer, to an individual exhibiting pain. An implantable device is chosen for a particular patient or pain indication such that an analgesically effective amount of buprenorphine will be continuously released. As used herein, the term “analgesically effective amount” refers to an amount of buprenorphine sufficient to achieve a reduction in or elimination of pain in a mammalian subject without loss of consciousness. The effectiveness of analgesia provided by an analgesic substance can be assessed by methods that are well known to those skilled in the art. For example, U.S. Pat. No. 6,228,863 describes assessment by direct measurement in human patients or by the use of one or more surrogate measures. Direct measurement may include scoring an analgesic questionnaire reported by patients at serial times following administration of the analgesic substance. Summary measures of analgesia include the sum of pain intensity difference (SPID) and total pain relief (TOTPAR). Surrogate measures for determining analgesic effectiveness in human subjects include assessment of sedation, respiratory rate and/or pupil size, and visual analogue scale for drug effect. Effectiveness of analgesia may also be assessed using animal models. For example, U.S. Pat. No. 4,599,342 describes a mouse hot plate test and a phenylquinone writhing test model for assessing the extent of analgesia.
  • [0036]
    The method of alleviating pain according to the present invention is applicable to the treatment of all pain conditions which require continuous administration of an analgesic substance, e.g., postoperative pain, cancer pain, arthritic pain, lumbosacral pain, musculoskeletal pain, neuropathic pain, etc. This list, however, should not be interpreted as exhaustive. It is contemplated that the method of the invention will improve compliance with dosing regimens for therapeutic pain relief, while reducing the amount of opiate substances that are available for diversion to nonintended users, i.e., drug addicts. Long term continuous release should also reduce or eliminate the peaks and troughs of blood analgesic concentration associated with other formulations such as oral dosage forms. Typically, the steady state release rate of buprenorphine used for pain relief methods is from about 0.1 to about 5, sometimes about 0.2 to about 1, often about 0.3 mg per day.
  • [0037]
    In any of the above methods, the length of time during which buprenorphine is continuously administered may be extended by reimplanting additional implantable devices in an individual receiving treatment before or after plasma levels of buprenorphine begin to decline, to maintain buprenorphine at the desired steady state level.
  • [0000]
    Kits
  • [0038]
    The invention also provides kits for use in treatment of opiate addiction or pain. The kits include at least one implantable, nonerodible device of the type herein described, capable of delivering long-term therapeutic levels of buprenorphine, in suitable packaging, along with instructions providing information to the user and/or health care provider regarding subcutaneous implantation and use of the system for treating drug dependence or pain. Kits may also include literature discussing performance of the implantable devices of the invention. Kits include a delivery system, i.e., one or a multiplicity of implantable devices, capable of providing sustained release of therapeutic levels of buprenorphine for at least about 3 months. Kits for treatment of opiate addiction typically contain a polymeric, nonerodible delivery system capable of continuously releasing buprenorphine at a rate sufficient to achieve a therapeutically effective plasma level of about 0.1 to about 70, about 1 to about 10, or about 1 to about 6 ng/ml for at least about 3 months. Kits for treatment of pain typically contain a delivery system capable of releasing a total continuous analgesically effective dosage of about 0.1 to about 5, about 0.2 to about 1, or about 0.3 mg buprenorphine per day for at least about 3 months. In kits of the invention, implantable devices may be preloaded into devices such as, for example, syringes or trocars, capable of administering them by subcutaneous implantation into patients.
  • EXAMPLES
  • [0039]
    The following examples are intended to illustrate but not limit the invention.
  • Example 1 Materials and Methods
  • [0040]
    Materials
  • [0041]
    The following materials were used:
      • Buprenorphine HCl, 99.3%, supplied by Macfarlan Smith Limited, Wheatfield Road, Edinburgh, EH 11 2QA
      • Buprenorphine base, supplied by Diosynth B.V. Vlijtseweg 130, 7317 AK Apeldoorn, The Netherlands
      • Buprenorphine HCl, supplied by Diosynth B.V. Vlijtseweg 130, 7317 AK Apeldoorn, The Netherlands
      • Methanol-ChromAR, HPLC grade, supplied by Mallinckrodt, St. Louis, Mo.
      • Acetonitrile, HPLC grade, supplied by Mallinckrodt, St. Louis, Mo.
      • Sodium lauryl sulfate, 99%, supplied by Sigma Chemicals, St. Louis, Mo.
      • EVA, 33% vinyl acetate, supplied by Equistar Chemicals, LP, Houston, Texas
      • Tower Plasti-Peel pouches, Catalog #30307PN, supplied by DRG Medical Packaging, Mundelein, Ill.
        Preparation of Implantable Devices
  • [0050]
    Buprenorphine is available as a salt (HCl) and as a free base. The implantable device is intended to release drug over a 3-month period or longer, so preliminary studies were performed to select the form of buprenorphine suitable for sustained release. Buprenorphine was incorporated at 50% drug load in the copolymer, using the free base form and the HCl salt. Extruded rods were prepared and comparative in vitro evaluations were conducted to select the drug form, based on the results of these studies.
  • [0051]
    Implantable devices were prepared using an extrusion process. As a result of initial loading experiments with lactose, two sets of extrusion parameters were identified that produced implantable devices with a smooth exterior finish and homogeneous drug content. The extrusion parameters were as follows:
    Set 1 Zone 1: 210° F.
    Zone 2: 230° F.
    Zone 3: 210° F.
    Die: 214° F.
    RPM: 67
    Die orifice: 2.18 mm
  • [0052]
    Set 1 parameters were used for the preparation of rods incorporating 50% buprenorphine free base and HCl salt.
    Set 2 Zone 1: 210° F.
    Zone 2: 230° F.
    Zone 3: 230° F.
    Die: 240° F.
    RPM: 40
    Die orifice: 1.95 mm
  • [0053]
    Set 2 parameters were used for the preparation of rods incorporating 75% buprenorphine HCl salt, which were used for in vitro and in vivo studies as described below.
  • [0054]
    The ground copolymer and compound to be incorporated were used as received from the manufacturer. The extruded rods were cut into uniform lengths of 25 mm, packaged in polyester/Tyvek bags, heat sealed, and shipped to Steris/Isomedix (Libertyville, Ill.) for terminal sterilization by gamma irradiation.
  • [0055]
    HPLC Assays
  • [0056]
    HPLC analysis was used to determine the rate of in vitro release of buprenorphine from buprenorphine-containing implants. Chromatography was performed using a Waters Novapak C-18 (150 mm×3.9 mm, SN. E5003B) column and 0.05 M sodium acetate, pH 5 (Solution A) and a mixture of methanol/acetonitrile (2:1 v/v) (Solution B) as the mobile phase, at a ratio of 35% A and 65% B and a flow rate of 1 ml/min. The injection volume was 100 μl. Detection was accomplished by means of a UV/VIS (Waters Model 490) detector at a wavelength of 285 nm. Instrument control and data acquisitions were facilitated using a Waters Millennium (V 2.15) software package. The external calibration was obtained using buprenorphine standard solutions prepared in 2:1 (v/v) acetonitrile:methanol.
  • [0057]
    The calibration curve for the buprenorphine standard over a concentration range of 2.5-500 μg/ml indicated linearity, with r2 values greater than 0.99.
  • [0000]
    LC/MS/MS Assay
  • [0058]
    An LC/MS/MS method was used to determine levels of buprenorphine released from the implants in vivo.
  • [0000]
    Buprenorphine
  • [0059]
    Dog plasma (0.500 ml) containing buprenorphine and a D4-buprenorphine internal standard was extracted with hexane/isoamyl alcohol. Following centrifugation, transfer of the organic layer and evaporation, the dried extract was derivatized with pentafluoropropionic anhydride (PFPA). After the reaction, the excess reagent was evaporated and an aliquot of the reconstituted extract was injected onto a SCIEX API III Plus LC-MS-MS apparatus in positive ion mode equipped with an HPLC column. Peak areas of the m/z 596 to 564 product ion of buprenorphine-PFP were measured against the m/z 600 to 568 product ion of the internal standard in MRM mode. Quantitation was performed using a weighted linear least squares regression analysis generated from spiked plasma calibration samples.
  • [0000]
    Norbuprenorphine
  • [0060]
    Dog plasma (0.500 ml) containing norbuprenorphine and a D3-norbuprenorphine internal standard was basified and extracted with ethyl acetate. Following evaporation, the dried extract was derivatized with acetic anhydride. After the reaction, the excess reagent was evaporated and an aliquot of the reconstituted extract was injected onto a SCIEX API III-Plus LC-MS-MS apparatus equipped with an HPLC column. Peak areas of the m/z 586 to 498 product ion of the norbuprenorphine derivative was measured against the peak areas of the m/z 589 to 501 product ion of the internal standard. Quantitation was performed using the peak areas of the m/z 589 to 501 product ion of the internal standard. Quantitation was performed using a weighted linear least squares regression analysis generated from fortified plasma calibration samples.
  • Example 2 In Vitro Characterization of Extruded Implantable Devices
  • [0061]
    Extruded rods prepared as described above were characterized for total drug load and for rate of drug release.
  • [0000]
    Assessment of Drug Loading
  • [0062]
    Extruded rods were accurately weighed, placed in tightly closed borosilicate glass jars containing 50 ml of methanol, and continuously stirred at room temperature. Sample aliquots were removed periodically and analyzed by HPLC. Initial experiments indicated that the incorporated compounds were completely extracted within 24 hr. Irradiated and nonirradiated rods were compared side by side.
  • [0063]
    Drug loading studies indicated that the physical mixtures were homogeneous and contained the estimated quantities of buprenorphine. Table 1 shows the recovery for the free base (FB) and HCl salt at 50% loading. Table 2 shows the recovery of buprenorphine HCl at 75% loading, and indicates that the average drug load before and after gamma radiation was>75%.
    TABLE 1
    Recovery of buprenorphine at 50% drug loading.
    Sample 1 Sample 2 Average
    Drug (% drug load) (% drug load) (% drug load)
    Buprenorphine HCl 51.0 49.6 50.3
    Buprenorphine FB 45.5 46.5 46.0
  • [0064]
    TABLE 2
    Recovery of buprenorphine HCl at 75% drug loading.
    Before Radiation After Radiation
    (% drug load) (% drug load)
    Average = 77.3 Average = 75.5
    SD = +/−4.2 SD = +/−3.6

    Assessment of Drug Release
  • [0065]
    Experiments were performed to determine the rate of buprenorphine released from the extruded rods. The medium for these studies was 0.5% sodium lauryl (dodecyl) sulfate (SDS). The preweighed rods were placed in 100 ml screw cap jars containing 50 ml of medium and placed on an orbital shaker. The orbital shaker was housed in an incubator maintained at 37° C. Sampling of the medium was performed by replacing the media periodically. The samples obtained were analyzed by HPLC.
  • [0066]
    Comparison of the in vitro release of buprenorphine base and salt form indicated that daily release for the HCl salt, after an initial burst, was closer than that of the free base to the desired range of about 1 mg/day (FIG. 1). Thus, the HCl salt was selected for further studies.
  • Example 3 In Vivo Evaluation of Drug Loaded Implantable Devices
  • [0067]
    Three female beagle dogs were administered two sterilized implantable devices each containing 75% buprenorphine HCl in EVA containing 33% vinyl acetate, as described above (2 mm diameter×2.6 cm length rods). Implantable devices were administered by subcutaneous injection to the dorsal region of each dog using a trocar. Blood samples were withdrawn periodically over a period of 84 days and frozen. The frozen samples were analyzed by LC/MS/MS for content of buprenorphine and norbuprenorphine (the major metabolite).
  • [0068]
    After an initial burst, the mean buprenorphine plasma levels were maintained around 0.75-1.0 ng/ml through day 84. The mean buprenorphine and norbuprenorphine levels were similar in all three dogs. The peak concentration of buprenorphine in the plasma ranged from 2.41 to 6.32 ng/ml. After the initial burst effect, a slow decrease in plasma concentration of buprenorphine was observed for all the dogs. On day 84, plasma concentration of buprenorphine ranged from 0.72 to 0.99 ng/ml. No signs of toxicity or irritation and/or inflammation at the sites of implantation were observed in any of the dogs. Further, no vascularization or minimal fibrous capsule formation were observed. The plasma concentration of buprenorphine over time for this experiment is shown in FIG. 2.
  • Example 4 Long Term Delivery of Buprenorphine via an Implantable Delivery System in Vivo
  • [0069]
    In vivo release of buprenorphine from polymeric implantable devices was investigated in toxicology studies in beagle dogs over an eight month period of time. Four dosage groups were treated with 2, 8, 16, or 24 implantable devices (rod-shaped devices containing 25% buprenorphine HCl and 75% EVA with 33% vinyl acetate, as described in Example 3). Implantable devices were administered subcutaneously in the dorsal regions of dogs via trocar under sterile conditions. Blood samples were collected from the jugular veins at various times for 8 months post implantation. Plasma concentrations of buprenorphine were quantified by LC/MS/MS. Animals were monitored for complications including irritation, inflammation, or infection at the treatment site. Pharmacokinetic parameters observed for the different dosage groups are represented in Table 3.
    TABLE 3
    Pharmacokinetic Parameters Calculated
    from Plasma Concentrations
    Mean Mean Mean
    Number of Cmax a tmax b Css c Half-Life to Css Number of
    Implants (ng/mL) (day) (ng/mL) (weeks) Dogs, n
    2 4.4 1 0.81 ± 0.1  0.7 3
    8 21.6 1 3.2 ± 0.4 2 2
    16 36.1 1 4.6 ± 0.5 2 2
    24 74.6 1 9.3 ± 0.7 2 10

    aMaximum concentration of buprenorphine achieved in plasma

    bTime of maximum plasma concentration of buprenorphine

    cMean steady-state plasma concentration
  • [0070]
    After an initial burst, pharmacokinetics were linear and dose proportional with 2 and 8 implantable devices, and were saturable and nonlinear with 16 and 24 devices (FIG. 3). Steady-state concentrations of 0.81±0.1 and 3.2±0.4 ng/ml were achieved within 3 weeks with 2 and 8 devices, respectively (FIG. 4). Steady-state concentrations of 4.6±0.5 and 9.3±0.7 ng/ml were achieved within 8 weeks with 16 devices and 10 weeks with 24 devices, respectively. Upon reaching steady state, buprenorphine levels remained steady, with a concentration variability of about 10-20%, until 8 months post implantation, at which time the implantable devices were removed. Norbuprenorphine plasma concentrations remained below detectable levels. The additional time required to reach steady state with 16-24 implantable devices may be attributable to limited diffusion of the drug due to saturation of the space between the devices and blood capillaries, or due to saturation of capillary absorptive surface area.
  • [0071]
    No significant systemic or local (implantation site) adverse effects were observed in any of the dogs. Minor irritation at the treatment site was observed in three dogs. No adverse behavioral effects were observed other than lethargy on the first day after implantation for animals receiving the maximum dosage (i.e., 24 devices). Upon removal of the devices after 8 months, no areas of necrosis or visible vascularization were observed in the tissue that had been surrounding the devices.
  • [0072]
    Although the foregoing invention has been described in some detail by way of illustration and examples for purposes of clarity of understanding, it will be apparent to those skilled in the art that certain changes and modifications may be practiced without departing from the spirit and scope of the invention. Therefore, the description should not be construed as limiting the scope of the invention, which is delineated by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety.

Claims (34)

  1. 1-36. (canceled)
  2. 37. An implantable device for treating opiate addiction, comprising buprenorphine and a biocompatible, nonerodible polymer, wherein said device comprises a polymeric matrix comprising buprenorphine blended with said polymer, and wherein when said implantable device is implanted subcutaneously in a mammal, said buprenorphine is continuously released in vivo over a sustained period of time through pores that open to the surface of said matrix at a rate that results in a steady state plasma buprenorphine level of at least about 0.1 ng/ml, wherein said device is washed with ethanol prior to subcutaneous implantation, wherein said device does not comprise a coating that is impermeable to buprenorphine, wherein said device does not comprise external medical equipment, and wherein said washing with ethanol removes surface buprenorphine and reduces the initial burst of buprenorphine released in vivo after subcutaneous implantation relative to an unwashed device.
  3. 38. An implantable device according to claim 37, wherein the polymeric matrix comprises ethylene vinyl acetate copolymer (EVA).
  4. 39. An implantable device according to claim 38, wherein said EVA comprises about 33% vinyl acetate.
  5. 40. An implantable device according to claim 39, comprising about 10 to about 85% buprenorphine.
  6. 41. An implantable device according to claim 40, comprising about 50% buprenorphine.
  7. 42. An implantable device according to claim 40, comprising about 75% buprenorphine.
  8. 43. An implantable device according to claim 39, wherein the implantable device is produced by an extrusion process.
  9. 44. An implantable device according to claim 43, comprising dimensions of about 1.5 to about 5 mm in diameter and about 0.5 to about 7 cm in length.
  10. 45. An implantable device according to claim 44, comprising dimensions of about 2.4 mm in diameter and about 2.6 cm in length.
  11. 46. An implantable device according to claim 45, wherein said implantable device releases about 1 mg buprenorphine per day in vitro.
  12. 47. An implantable device according to claim 46, wherein the sustained period of time is at least about 3 months.
  13. 48. An implantable device for treating pain, comprising buprenorphine and a biocompatible, nonerodible polymer, wherein said device comprises a polymeric matrix comprising buprenorphine blended with said polymer, and wherein when said implantable device is subcutaneously implanted in a mammal, said buprenorphine is continuously released in vivo over a sustained period of time through pores that open to the surface of said matrix at a steady state rate of at least about 0.1 mg per day, wherein said device is washed with ethanol prior to subcutaneous implantation, wherein said device does not comprise a coating that is impermeable to buprenorphine, wherein said device does not comprise external medical equipment, and wherein said washing with ethanol removes surface buprenorphine and reduces the initial burst of buprenorphine released in vivo after subcutaneous implantation relative to an unwashed device.
  14. 49. An implantable device according to claim 48, wherein the polymeric matrix comprises EVA.
  15. 50. An implantable device according to claim 49, wherein said EVA comprises 33% vinyl acetate.
  16. 51. An implantable device according to claim 50, comprising about 10 to about 85% buprenorphine.
  17. 52. An implantable device according to claim 51, comprising about 50% buprenorphine.
  18. 53. An implantable device according to claim 51, comprising about 75% buprenorphine.
  19. 54. An implantable device according to claim 50, wherein the implantable device is produced by an extrusion process.
  20. 55. An implantable device according to claim 54, comprising dimensions of about 1.5 to about 5 mm in diameter and about 0.5 to about 7 cm in length.
  21. 56. An implantable device according to claim 55, comprising dimensions of about 2.4 mm in diameter and about 2.6 cm in length.
  22. 57. An implantable device according to claim 56, wherein said implantable device releases about 1 mg buprenorphine per day in vitro.
  23. 58. An implantable device according to claim 57, wherein the sustained period of time is at least about 3 months.
  24. 59. A kit for use in treatment of opiate addiction, comprising at least one implantable device according to claim 37, and instructions for use.
  25. 60. A kit for use in treatment of pain, comprising at least one implantable device according to claim 48, and instructions for use.
  26. 61. An implantable device according to claim 37, wherein said device is washed in ethanol for 30 minutes
  27. 62. An implantable device according to claim 48, wherein said device is washed in ethanol for 30 minutes.
  28. 63. A process for producing a subcutaneously implantable device comprising buprenorphine and a biocompatible, nonerodible polymeric matrix, said process comprising washing said device in a solution in which buprenorphine is soluble, wherein the initial burst of buprenorphine released in vivo after subcutaneous implantation is reduced relative to an unwashed device.
  29. 64. A process according to claim 63, wherein said device is washed in ethanol.
  30. 65. A process according to claim 64, wherein said device is washed in ethanol for 30 minutes.
  31. 66. A delivery system for treatment of opiate addiction, comprising a multiplicity of implantable devices according to claim 37, wherein when said multiplicity of devices is implanted subcutaneously in a mammal, buprenorphine is continuously released in vivo at a rate that results in a therapeutically effective steady state plasma level for treatment of opiate addiction.
  32. 67. A delivery system for treatment of pain, comprising a multiplicity of implantable devices according to claim 48, wherein when said multiplicity of devices is implanted subcutaneously in a mammal, buprenorphine is continuously released in vivo at a rate that results in an analgesically effective steady state rate for treatment of pain.
  33. 68. A kit for use in treatment of opiate addiction, comprising a delivery system according to claim 66.
  34. 69. A kit for use in treatment of pain, comprising a delivery system according to claim 67.
US11801302 2002-05-31 2007-05-08 Implantable polymeric device for sustained release of buprenorphine Abandoned US20080026031A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US38473302 true 2002-05-31 2002-05-31
US10453377 US7736665B2 (en) 2002-05-31 2003-06-02 Implantable polymeric device for sustained release of buprenorphine
US11801302 US20080026031A1 (en) 2002-05-31 2007-05-08 Implantable polymeric device for sustained release of buprenorphine

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11801302 US20080026031A1 (en) 2002-05-31 2007-05-08 Implantable polymeric device for sustained release of buprenorphine
US13691379 US20130171229A1 (en) 2002-05-31 2012-11-30 Implantable polymeric device for sustained release of buprenorphine
US14091296 US20140088131A1 (en) 2002-05-31 2013-11-26 Implantable Polymeric Device for Sustained Release of Buprenorphine
US14091306 US20140163057A1 (en) 2002-05-31 2013-11-26 Implantable Polymeric Device for Sustained Release of Buprenorphine
US14091309 US20140171457A1 (en) 2002-05-31 2013-11-26 Implantable Polymeric Device for Sustained Release of Buprenorphine
US14091301 US20140161860A1 (en) 2002-05-31 2013-11-26 Implantable Polymeric Device for Sustained Release of Buprenorphine
US15165641 US20160367477A1 (en) 2002-05-31 2016-05-26 Implantable polymeric device for sustained release of buprenorphine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10453377 Continuation US7736665B2 (en) 2002-05-31 2003-06-02 Implantable polymeric device for sustained release of buprenorphine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13691379 Continuation US20130171229A1 (en) 2002-05-31 2012-11-30 Implantable polymeric device for sustained release of buprenorphine

Publications (1)

Publication Number Publication Date
US20080026031A1 true true US20080026031A1 (en) 2008-01-31

Family

ID=29712085

Family Applications (8)

Application Number Title Priority Date Filing Date
US10453377 Active 2024-06-09 US7736665B2 (en) 2002-05-31 2003-06-02 Implantable polymeric device for sustained release of buprenorphine
US11801302 Abandoned US20080026031A1 (en) 2002-05-31 2007-05-08 Implantable polymeric device for sustained release of buprenorphine
US13691379 Abandoned US20130171229A1 (en) 2002-05-31 2012-11-30 Implantable polymeric device for sustained release of buprenorphine
US14091301 Abandoned US20140161860A1 (en) 2002-05-31 2013-11-26 Implantable Polymeric Device for Sustained Release of Buprenorphine
US14091309 Abandoned US20140171457A1 (en) 2002-05-31 2013-11-26 Implantable Polymeric Device for Sustained Release of Buprenorphine
US14091296 Pending US20140088131A1 (en) 2002-05-31 2013-11-26 Implantable Polymeric Device for Sustained Release of Buprenorphine
US14091306 Abandoned US20140163057A1 (en) 2002-05-31 2013-11-26 Implantable Polymeric Device for Sustained Release of Buprenorphine
US15165641 Pending US20160367477A1 (en) 2002-05-31 2016-05-26 Implantable polymeric device for sustained release of buprenorphine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10453377 Active 2024-06-09 US7736665B2 (en) 2002-05-31 2003-06-02 Implantable polymeric device for sustained release of buprenorphine

Family Applications After (6)

Application Number Title Priority Date Filing Date
US13691379 Abandoned US20130171229A1 (en) 2002-05-31 2012-11-30 Implantable polymeric device for sustained release of buprenorphine
US14091301 Abandoned US20140161860A1 (en) 2002-05-31 2013-11-26 Implantable Polymeric Device for Sustained Release of Buprenorphine
US14091309 Abandoned US20140171457A1 (en) 2002-05-31 2013-11-26 Implantable Polymeric Device for Sustained Release of Buprenorphine
US14091296 Pending US20140088131A1 (en) 2002-05-31 2013-11-26 Implantable Polymeric Device for Sustained Release of Buprenorphine
US14091306 Abandoned US20140163057A1 (en) 2002-05-31 2013-11-26 Implantable Polymeric Device for Sustained Release of Buprenorphine
US15165641 Pending US20160367477A1 (en) 2002-05-31 2016-05-26 Implantable polymeric device for sustained release of buprenorphine

Country Status (7)

Country Link
US (8) US7736665B2 (en)
EP (2) EP2561860B1 (en)
JP (1) JP4668611B2 (en)
CA (1) CA2487577C (en)
DK (1) DK2561860T3 (en)
ES (1) ES2665999T3 (en)
WO (1) WO2003101358A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033250A1 (en) * 2002-05-31 2004-02-19 Patel Rajesh A. Implantable polymeric device for sustained release of buprenorphine
US20050031668A1 (en) * 2003-05-30 2005-02-10 Patel Rajesh A. Implantable polymeric device for sustained release of nalmefene
US20080311171A1 (en) * 2003-03-31 2008-12-18 Patel Rajesh A Implantable polymeric device for sustained release of dopamine agonist
US20090130056A1 (en) * 2007-11-21 2009-05-21 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
WO2011116132A1 (en) 2010-03-16 2011-09-22 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US8541028B2 (en) 2004-08-04 2013-09-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2218448B1 (en) 2002-12-13 2015-09-23 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
DE602005008247D1 (en) * 2004-06-04 2008-08-28 Camurus Ab Liquid depot formulations
US9937164B2 (en) 2012-07-26 2018-04-10 Camurus Ab Opioid formulations
EP2415484B1 (en) 2004-09-17 2014-06-18 Durect Corporation Sustained local anesthetic composition containing SAIB
WO2007139744A3 (en) * 2006-05-23 2008-11-06 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
EP2117521B1 (en) 2006-11-03 2012-06-27 Durect Corporation Transdermal delivery systems comprising bupivacaine
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
US20090093875A1 (en) * 2007-05-01 2009-04-09 Abbott Laboratories Drug eluting stents with prolonged local elution profiles with high local concentrations and low systemic concentrations
DE602007005939D1 (en) * 2007-07-10 2010-05-27 Clariant Finance Bvi Ltd A method for measuring octanol-water partition coefficient of surfactants
JP2011506319A (en) 2007-12-06 2011-03-03 デュレクト コーポレーション Pain, methods useful in the treatment of inflammation associated with an arthritic condition or chronic disease,
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
JP5675820B2 (en) * 2009-09-22 2015-02-25 エボニック コーポレイションEvonik Corporation Implant device having a variety of bioactive agents carrying arrangement
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481018B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
EP2707032A1 (en) * 2011-05-10 2014-03-19 Antecip Bioventures II LLC Implantable polymeric device for sustained release of sufentanil
CA2853279A1 (en) 2011-10-24 2013-05-02 Endo Pharmaceuticals Inc. Cyclohexylamines
WO2013126552A1 (en) * 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US9944637B2 (en) 2013-12-16 2018-04-17 Asana Biosciences, Llc P2X3 and/or P2X2/3 compounds and methods
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2017210668A1 (en) * 2016-06-03 2017-12-07 Jt Pharmaceuticals, Inc. Sustained release compositions of kappa-opioid receptor agonist

Citations (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689634A (en) * 1966-01-06 1972-09-05 Ceskoslovenska Akademie Ved Protracted activity oral hydrogel bead
US3717639A (en) * 1967-05-04 1973-02-20 Little Inc A Process for the preparation of 1-(2-nitro-3,4-di-lower-alkoxybenzyl)isoquinolines
US3814768A (en) * 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US3923939A (en) * 1974-06-07 1975-12-02 Alza Corp Process for improving release kinetics of a monolithic drug delivery device
US4069307A (en) * 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US4148871A (en) * 1977-10-11 1979-04-10 Pitt Colin G Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4450150A (en) * 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4535157A (en) * 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
US4582835A (en) * 1983-12-06 1986-04-15 Reckitt & Colman Products Limited Analgesic compositions
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4661492A (en) * 1984-11-30 1987-04-28 Reckitt & Colman Products Limited Analgesic compositions
US4670014A (en) * 1984-02-21 1987-06-02 Bioetica S.A. Implantable, biocompatible reservoirs permitting conservation, cellular culturing, or controlled liberation of an active principle
US4678809A (en) * 1985-02-01 1987-07-07 Michael Phillips Injectable fomulations of disulfiram for the treatment of alcoholism
US4692451A (en) * 1985-12-11 1987-09-08 Trustees Of Tufts College Method for preventing stereotypic behavior in animals
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4898733A (en) * 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US4935428A (en) * 1987-12-03 1990-06-19 Reckitt & Colman Products Limited Treating opiate dependence
US4957119A (en) * 1987-08-08 1990-09-18 Akzo N.V. Contraceptive implant
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4983586A (en) * 1987-12-30 1991-01-08 University Of Florida Pharmaceutical formulations for parenteral use
US4994281A (en) * 1986-11-12 1991-02-19 Sanraku Incorporated Polylactic acid microspheres and process for producing the same
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
US5114718A (en) * 1990-09-20 1992-05-19 The Procter & Gamble Company Sustained release compositions for treating periodontol disease
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
US5156844A (en) * 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
US5211951A (en) * 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
US5219858A (en) * 1990-03-27 1993-06-15 Parnell Pharmaceuticals, Inc. Method and compositions for effecting withdrawal from drug dependency
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5298017A (en) * 1992-12-29 1994-03-29 Alza Corporation Layered electrotransport drug delivery system
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5574052A (en) * 1986-03-17 1996-11-12 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5601835A (en) * 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
US5604198A (en) * 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US5618553A (en) * 1994-10-26 1997-04-08 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US5618555A (en) * 1994-05-06 1997-04-08 Itto Denko Corporation Percutaneous absorption preparation
US5633000A (en) * 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5651986A (en) * 1994-08-02 1997-07-29 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5654008A (en) * 1993-11-19 1997-08-05 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5718921A (en) * 1987-03-13 1998-02-17 Massachusetts Institute Of Technology Microspheres comprising polymer and drug dispersed there within
US5732717A (en) * 1995-08-15 1998-03-31 Eli Lilly And Company Method for treating substance abuse withdrawal
US5750136A (en) * 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
US5756483A (en) * 1993-03-26 1998-05-26 Merkus; Franciscus W. H. M. Pharmaceutical compositions for intranasal administration of apomorphine
US5770606A (en) * 1994-04-22 1998-06-23 Pentech Pharmaceuticals, Inc. Dosage forms and method for ameliorating male erectile dysfunction
US5770231A (en) * 1993-11-19 1998-06-23 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles 1,2-benzisothiazoles
US5840719A (en) * 1993-05-28 1998-11-24 Eisai Company, Ltd. Apoptosis inhibitors for treating neurodegenerative diseases
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5980927A (en) * 1995-02-10 1999-11-09 Medtronic, Inc. Method and apparatus for administering analgesics, and method for making same device
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6117454A (en) * 1994-02-28 2000-09-12 Medinova Medical Consulting Gmbh Drug targeting to the nervous system by nanoparticles
US6203813B1 (en) * 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US6271240B1 (en) * 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
US20010036469A1 (en) * 1997-01-13 2001-11-01 Gooberman Lance L. Opiate antagonist implant and process for preparation therefor
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US20020034534A1 (en) * 1999-12-16 2002-03-21 Barr Deborah P. System and method for delivering a therapeutic agent over an extended period of time in conjuction with a receptor loading dose of the therapeutic agent
US20020049232A1 (en) * 2000-10-12 2002-04-25 Svensson Kjell A. Method of treating parkinson's disease
US6461485B2 (en) * 1998-01-14 2002-10-08 Kabushiki Kaisha Toshiba Sputtering method for forming an aluminum or aluminum alloy fine wiring pattern
US6512009B1 (en) * 1998-03-26 2003-01-28 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US20030039689A1 (en) * 2001-04-26 2003-02-27 Jianbing Chen Polymer-based, sustained release drug delivery system
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US20040009222A1 (en) * 2002-05-07 2004-01-15 Control Delivery Systems, Inc. Processes for forming a drug delivery device
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20040033250A1 (en) * 2002-05-31 2004-02-19 Patel Rajesh A. Implantable polymeric device for sustained release of buprenorphine
US20050031667A1 (en) * 2003-03-31 2005-02-10 Patel Rajesh A. Implantable polymeric device for sustained release of dopamine agonist
US20050031668A1 (en) * 2003-05-30 2005-02-10 Patel Rajesh A. Implantable polymeric device for sustained release of nalmefene
US20050245541A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US7270830B2 (en) * 2002-12-13 2007-09-18 Purdue Pharma L.P. Transdermal buprenorphine dosage regimen for analgesia
US20070275031A1 (en) * 2006-05-23 2007-11-29 Patel Rajesh A Implantable polymeric device for sustained release of buprenorphine with minimal initial burst

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5810519A (en) 1981-07-10 1983-01-21 Reckitt & Colmann Prod Ltd Medicinal composition
EP0226061B1 (en) 1985-12-17 1994-02-16 United States Surgical Corporation High molecular weight bioresorbable polymers and implantation devices thereof
US4844903A (en) * 1986-11-07 1989-07-04 Mepha Ag Process for the production of an adhesive plaster
CA2062746C (en) 1989-06-21 1999-02-02 Patrick Aebischer Neurological therapy system
US4968091A (en) * 1989-08-02 1990-11-06 Mariol John V Article useful as booster chair and as step stool
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
DE69129770T2 (en) 1990-04-13 1998-11-19 Takeda Chemical Industries Ltd Biodegradable high molecular polymers, their preparation and their use
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
FR2695826B1 (en) * 1992-09-21 1995-01-06 Theramex Novel pharmaceutical compositions based on derivatives of nomegestrol and processes for obtaining them.
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5503844A (en) * 1993-05-18 1996-04-02 Mli Acquisition Corp. Ii Foam laminate transdermal patch
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
JP3720386B2 (en) 1993-12-27 2005-11-24 住友製薬株式会社 Controlled drug release formulations
US6083534A (en) * 1995-03-01 2000-07-04 Yeda Research And Development Co. Ltd. Pharmaceutical compositions for controlled release of soluble receptors
US5587381A (en) 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
US5590876A (en) * 1995-04-03 1997-01-07 Hasbro, Inc. Ball tossing device
US6004962A (en) 1995-09-11 1999-12-21 Gooberman; Lance L. Rapid opioid detoxification
US5733565A (en) * 1996-02-23 1998-03-31 The Population Council, Center For Biomedical Research Male contraceptive implant
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6001845A (en) 1998-06-19 1999-12-14 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
ES2230154T3 (en) 1999-08-27 2005-05-01 Southern Research Institute Buprenorphine injectable compositions and their use for reducing the consumption of heroin and alcohol.
US20020198574A1 (en) 2001-06-22 2002-12-26 Ron Gumpert Automatic sobriety training and reconditioning system

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689634A (en) * 1966-01-06 1972-09-05 Ceskoslovenska Akademie Ved Protracted activity oral hydrogel bead
US3717639A (en) * 1967-05-04 1973-02-20 Little Inc A Process for the preparation of 1-(2-nitro-3,4-di-lower-alkoxybenzyl)isoquinolines
US4069307A (en) * 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3814768A (en) * 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4450150A (en) * 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US3923939A (en) * 1974-06-07 1975-12-02 Alza Corp Process for improving release kinetics of a monolithic drug delivery device
US4148871A (en) * 1977-10-11 1979-04-10 Pitt Colin G Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4535157A (en) * 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4582835A (en) * 1983-12-06 1986-04-15 Reckitt & Colman Products Limited Analgesic compositions
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4670014A (en) * 1984-02-21 1987-06-02 Bioetica S.A. Implantable, biocompatible reservoirs permitting conservation, cellular culturing, or controlled liberation of an active principle
US4661492A (en) * 1984-11-30 1987-04-28 Reckitt & Colman Products Limited Analgesic compositions
US4678809A (en) * 1985-02-01 1987-07-07 Michael Phillips Injectable fomulations of disulfiram for the treatment of alcoholism
US4898733A (en) * 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US4692451A (en) * 1985-12-11 1987-09-08 Trustees Of Tufts College Method for preventing stereotypic behavior in animals
US5935975A (en) * 1986-03-17 1999-08-10 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5574052A (en) * 1986-03-17 1996-11-12 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5726190A (en) * 1986-03-17 1998-03-10 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4994281A (en) * 1986-11-12 1991-02-19 Sanraku Incorporated Polylactic acid microspheres and process for producing the same
US5718921A (en) * 1987-03-13 1998-02-17 Massachusetts Institute Of Technology Microspheres comprising polymer and drug dispersed there within
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5601835A (en) * 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4957119A (en) * 1987-08-08 1990-09-18 Akzo N.V. Contraceptive implant
US5156844A (en) * 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
US4935428A (en) * 1987-12-03 1990-06-19 Reckitt & Colman Products Limited Treating opiate dependence
US4983586A (en) * 1987-12-30 1991-01-08 University Of Florida Pharmaceutical formulations for parenteral use
US5024998A (en) * 1987-12-30 1991-06-18 University Of Florida Pharmaceutical formulations for parenteral use
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5750136A (en) * 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5219858A (en) * 1990-03-27 1993-06-15 Parnell Pharmaceuticals, Inc. Method and compositions for effecting withdrawal from drug dependency
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5114718A (en) * 1990-09-20 1992-05-19 The Procter & Gamble Company Sustained release compositions for treating periodontol disease
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5211951A (en) * 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5298017A (en) * 1992-12-29 1994-03-29 Alza Corporation Layered electrotransport drug delivery system
US5756483A (en) * 1993-03-26 1998-05-26 Merkus; Franciscus W. H. M. Pharmaceutical compositions for intranasal administration of apomorphine
US5840719A (en) * 1993-05-28 1998-11-24 Eisai Company, Ltd. Apoptosis inhibitors for treating neurodegenerative diseases
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5770231A (en) * 1993-11-19 1998-06-23 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles 1,2-benzisothiazoles
US5965168A (en) * 1993-11-19 1999-10-12 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5654008A (en) * 1993-11-19 1997-08-05 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US6117454A (en) * 1994-02-28 2000-09-12 Medinova Medical Consulting Gmbh Drug targeting to the nervous system by nanoparticles
US5770606A (en) * 1994-04-22 1998-06-23 Pentech Pharmaceuticals, Inc. Dosage forms and method for ameliorating male erectile dysfunction
US5618555A (en) * 1994-05-06 1997-04-08 Itto Denko Corporation Percutaneous absorption preparation
US5604198A (en) * 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US5858388A (en) * 1994-06-23 1999-01-12 Axxia Technologies Subcutaneous implant for delivery of hydromorphone
US6126956A (en) * 1994-06-23 2000-10-03 Axxia Technologies Subcutaneous implant
US5633000A (en) * 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5651986A (en) * 1994-08-02 1997-07-29 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5618553A (en) * 1994-10-26 1997-04-08 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US5939094A (en) * 1994-12-23 1999-08-17 Pentech Pharamaceticals, Inc. Transdermal administration of apomorphine
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5980927A (en) * 1995-02-10 1999-11-09 Medtronic, Inc. Method and apparatus for administering analgesics, and method for making same device
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US5732717A (en) * 1995-08-15 1998-03-31 Eli Lilly And Company Method for treating substance abuse withdrawal
US6271240B1 (en) * 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6203813B1 (en) * 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
US20010036469A1 (en) * 1997-01-13 2001-11-01 Gooberman Lance L. Opiate antagonist implant and process for preparation therefor
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6344212B2 (en) * 1997-02-24 2002-02-05 Euro-Celtique S.A. Method of providing sustained analgesia with buprenorphine
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US6461485B2 (en) * 1998-01-14 2002-10-08 Kabushiki Kaisha Toshiba Sputtering method for forming an aluminum or aluminum alloy fine wiring pattern
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6512009B1 (en) * 1998-03-26 2003-01-28 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US6136818A (en) * 1998-06-19 2000-10-24 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US20020034534A1 (en) * 1999-12-16 2002-03-21 Barr Deborah P. System and method for delivering a therapeutic agent over an extended period of time in conjuction with a receptor loading dose of the therapeutic agent
US20020049232A1 (en) * 2000-10-12 2002-04-25 Svensson Kjell A. Method of treating parkinson's disease
US20030039689A1 (en) * 2001-04-26 2003-02-27 Jianbing Chen Polymer-based, sustained release drug delivery system
US20040009222A1 (en) * 2002-05-07 2004-01-15 Control Delivery Systems, Inc. Processes for forming a drug delivery device
US20040033250A1 (en) * 2002-05-31 2004-02-19 Patel Rajesh A. Implantable polymeric device for sustained release of buprenorphine
US7270830B2 (en) * 2002-12-13 2007-09-18 Purdue Pharma L.P. Transdermal buprenorphine dosage regimen for analgesia
US20050031667A1 (en) * 2003-03-31 2005-02-10 Patel Rajesh A. Implantable polymeric device for sustained release of dopamine agonist
US20090162412A1 (en) * 2003-03-31 2009-06-25 Patel Rajesh A Implantable polymeric device for sustained release of dopamine agonist
US20050031668A1 (en) * 2003-05-30 2005-02-10 Patel Rajesh A. Implantable polymeric device for sustained release of nalmefene
US20050245541A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US20070275031A1 (en) * 2006-05-23 2007-11-29 Patel Rajesh A Implantable polymeric device for sustained release of buprenorphine with minimal initial burst

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033250A1 (en) * 2002-05-31 2004-02-19 Patel Rajesh A. Implantable polymeric device for sustained release of buprenorphine
US7736665B2 (en) 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US20080311171A1 (en) * 2003-03-31 2008-12-18 Patel Rajesh A Implantable polymeric device for sustained release of dopamine agonist
US8852623B2 (en) 2003-03-31 2014-10-07 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
US20090162412A1 (en) * 2003-03-31 2009-06-25 Patel Rajesh A Implantable polymeric device for sustained release of dopamine agonist
US9278163B2 (en) 2003-03-31 2016-03-08 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
US20050031668A1 (en) * 2003-05-30 2005-02-10 Patel Rajesh A. Implantable polymeric device for sustained release of nalmefene
US8541028B2 (en) 2004-08-04 2013-09-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
US20090130056A1 (en) * 2007-11-21 2009-05-21 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
WO2011116132A1 (en) 2010-03-16 2011-09-22 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery

Also Published As

Publication number Publication date Type
CA2487577C (en) 2014-11-18 grant
US20140163057A1 (en) 2014-06-12 application
EP2561860A1 (en) 2013-02-27 application
EP1509182A4 (en) 2009-12-30 application
DK2561860T3 (en) 2018-04-30 grant
US7736665B2 (en) 2010-06-15 grant
US20140161860A1 (en) 2014-06-12 application
JP2005528422A (en) 2005-09-22 application
US20140088131A1 (en) 2014-03-27 application
US20140171457A1 (en) 2014-06-19 application
US20040033250A1 (en) 2004-02-19 application
US20130171229A1 (en) 2013-07-04 application
CA2487577A1 (en) 2003-12-11 application
WO2003101358A1 (en) 2003-12-11 application
EP1509182A1 (en) 2005-03-02 application
EP2561860B1 (en) 2018-02-28 grant
US20160367477A1 (en) 2016-12-22 application
JP4668611B2 (en) 2011-04-13 grant
ES2665999T3 (en) 2018-04-30 grant

Similar Documents

Publication Publication Date Title
Cador et al. Evidence of a complete independence of the neurobiological substrates for the induction and expression of behavioral sensitization to amphetamine
Pascoe Opioid analgesics
EP0301856B1 (en) Delivery system
US4668684A (en) Combination of flupirtin and anticholinergic acting spasmolytic
Kalivas et al. Enkephalin action on the mesolimbic system: a dopamine-dependent and a dopamine-independent increase in locomotor activity.
US6306425B1 (en) Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
US5403595A (en) Controlled, sustained release delivery system for smoking cessation
Yang et al. Controlled delivery of 1, 3-bis (2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer
Murray et al. Hydromorphone
Heller et al. Poly (ortho esters)–their development and some recent applications
Park et al. Biodegradable polyanhydride devices of cefazolin sodium, bupivacaine, and taxol for local drug delivery: preparation, and kinetics and mechanism of in vitro release
US6913760B2 (en) Drug delivery composition
US5075341A (en) Treatment for cocaine abuse
US6214387B1 (en) Biodegradable polymer matrices for sustained delivery of local anesthetic agents
USRE37410E1 (en) Controlled local delivery of chemotherapeutic agents for treating solid tumors
Xi et al. Selective dopamine D3 receptor antagonism by SB‐277011A attenuates cocaine reinforcement as assessed by progressive‐ratio and variable‐cost–variable‐payoff fixed‐ratio cocaine self‐administration in rats
Coombs et al. Neuropathologic lesions and CSF morphine concentrations during chronic continuous intraspinal morphine infusion. A clinical and post-mortem study
US20030130314A1 (en) Analgesic delivery systems and methods of use
US20040162308A1 (en) Use of methylnaltrexone and related compounds for treatment of constipation caused by endogenous opioids
Jankovic et al. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders
US5858393A (en) Transdermal formulation
US5618563A (en) Biodegradable polymer matrices for sustained delivery of local anesthetic agents
Wright et al. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer
WO2008153611A2 (en) Sustained delivery formulations of risperidone compounds
US5858388A (en) Subcutaneous implant for delivery of hydromorphone

Legal Events

Date Code Title Description
AS Assignment

Owner name: TITAN PHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PATEL, RAJESH A.;BUCALO, LOUIS R.;REEL/FRAME:019377/0576

Effective date: 20030815

AS Assignment

Owner name: OXFORD FINANCE CORPORATION, VIRGINIA

Free format text: SECURITY AGREEMENT;ASSIGNOR:TITAN PHARMACEUTICALS, INC.;REEL/FRAME:023699/0096

Effective date: 20091223

Owner name: OXFORD FINANCE CORPORATION,VIRGINIA

Free format text: SECURITY AGREEMENT;ASSIGNOR:TITAN PHARMACEUTICALS, INC.;REEL/FRAME:023699/0096

Effective date: 20091223

AS Assignment

Owner name: TITAN PHARMACEUTICALS, INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:OXFORD FINANCE CORPORATION;REEL/FRAME:026084/0908

Effective date: 20110406

AS Assignment

Owner name: TITAN PHARMACEUTICALS, INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:OXFORD FINANCE LLC;REEL/FRAME:044802/0909

Effective date: 20180129

Owner name: TITAN PHARMACEUTICALS, INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:OXFORD FINANCE CORPORATION;REEL/FRAME:044803/0064

Effective date: 20180129